Insight

Ilya Tsimafeyeu Presented Phase 2 SBRT Trial in Oligoprogressive Urothelial Cancer on Avelumab at ASCO 2025

Ilya Tsimafeyeu/bucare.org

Jun 7, 2025, 05:44

Ilya Tsimafeyeu Presented Phase 2 SBRT Trial in Oligoprogressive Urothelial Cancer on Avelumab at ASCO 2025

Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:

“Our randomized phase 2 study of stereotactic body radiation therapy in patients with oligoprogressive metastatic urothelial cancer receiving maintenance avelumab was announced at the Trials in Progress session at ASCO25.”

Urothelial Cancer

More posts featuring Ilya Tsimafeyeu on OncoDaily.

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

Highlights from ASCO 2025 Day 4

Urothelial Cancer

ASCO ASCO 2025 ASCO25 Avelumab Bureau of Cancer Research cancer Ilya Tsimafeyeu Oligoprogressive Urothelial Cancer OncoDaily Oncology radiation therapy

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders